- Home
- SEER vs IVA Comparison
SEER vs IVA Comparison
Compare SEER & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- IVA
- Stock Information
- Founded
- SEER 2017
- IVA 2011
- Country
- SEER United States
- IVA France
- Employees
- SEER 147
- IVA N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- IVA Health Care
- Exchange
- SEER Nasdaq
- IVA Nasdaq
- Market Cap
- SEER 135.0M
- IVA 117.3M
- IPO Year
- SEER 2020
- IVA 2020
- Fundamental
- Price
- SEER $2.29
- IVA $2.16
- Analyst Decision
- SEER Hold
- IVA Strong Buy
- Analyst Count
- SEER 1
- IVA 4
- Target Price
- SEER $3.00
- IVA $13.25
- AVG Volume (30 Days)
- SEER 200.2K
- IVA 7.3K
- Earning Date
- SEER 02-27-2025
- IVA 09-25-2024
- Dividend Yield
- SEER N/A
- IVA N/A
- EPS Growth
- SEER N/A
- IVA N/A
- EPS
- SEER N/A
- IVA N/A
- Revenue
- SEER $14,608,000.00
- IVA $20,652,523.00
- Revenue This Year
- SEER N/A
- IVA N/A
- Revenue Next Year
- SEER $34.78
- IVA $361.78
- P/E Ratio
- SEER N/A
- IVA N/A
- Revenue Growth
- SEER N/A
- IVA N/A
- 52 Week Low
- SEER $1.51
- IVA $1.53
- 52 Week High
- SEER $2.63
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- SEER 45.45
- IVA 38.30
- Support Level
- SEER $2.23
- IVA $2.11
- Resistance Level
- SEER $2.37
- IVA $2.24
- Average True Range (ATR)
- SEER 0.11
- IVA 0.07
- MACD
- SEER -0.01
- IVA 0.01
- Stochastic Oscillator
- SEER 41.43
- IVA 22.07
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.